What Pardini Group does

Pardini Group (legal name Grupo Hermes Pardini, public ticker PARDINI on B3 Novo Mercado) is a Brazilian diagnostic medicine company founded in 1959 by Dr. Hermes Pardini in Belo Horizonte, Minas Gerais, now headquartered in Vespasiano. The group operates an integrated diagnostic platform combining 125 owned service units, approximately 6,000 partner laboratories served via the Lab-to-Lab B2B channel, and coverage reaching 1,930-2,000+ Brazilian municipalities. It offers more than 8,000 test types spanning clinical analysis, diagnostic imaging, vaccination, cryopreservation, human and veterinary genetics, toxicology, oncology genomics, and personalized medicine, organized across 14 brands including Hermes Pardini (flagship), Padrão, Diagnostika, Progenetica, CMNG, Ecoar, Humberto Abrão, Labfar, DLE, Biocod, Toxicologia Pardini, Solução, My Pardini, and Telemedicina Pardini.

The underlying technology stack is anchored by the Vespasiano-based Núcleo Técnico Operacional (NTO), described as the world's largest specialized laboratory production hub by installed capacity and capable of processing more than 5 million tests per month via parallel automated and semi-automated lines. The 2020-launched Enterprise platform extends this to seven interconnected production nuclei (central nucleus near Belo Horizonte International Airport plus six advanced nuclei) with combined capacity for 160 million tests annually, real-time command center monitoring, and a Just-in-Time reagent model replacing direct procurement. Advanced diagnostic modalities include Next-Generation Sequencing with CNV analysis for hereditary cancer panels and HRD/HRR panels, LC-MS/MS mass spectrometry enabling newborn screening for over 300 treatable diseases, PD-L1 immunohistochemistry on VENTANA BenchMark ULTRA, and the Guardian automated molecular biology platform operating Brazil's largest COVID-19 RT-PCR testing center at 20,000 tests per day. R$200 million+ has been invested in technology infrastructure.

The business model operates four parallel revenue streams: (1) direct patient services at owned units billed primarily through health insurance operators on a transactional fee basis, (2) Lab-to-Lab B2B professional services and specialized testing to approximately 6,000 partner laboratories, (3) enterprise billing to health insurance operators and self-management plans via a dedicated commercial team, and (4) specialized professional services in toxicology (10,000+ corporate clients) and personalized medicine (600+ physicians, 3 million+ tests performed last year). The Pardini family retains 64.7% ownership post-IPO; the company has executed more than 12 acquisitions between 2012-2019 to build geographic and specialty breadth, and pursues an explicit strategy of democratizing access to advanced diagnostics across urban and rural Brazil through the Enterprise logistics network.

Name

Pardini Group

Legal name

Grupo Hermes Pardini

Website

https://grupopardini.com.br

Company type

Public

Founded year

1959

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Grupo Pardini is a publicly listed Brazilian diagnostic medicine company serving patients, 6,000+ partner laboratories, health insurers, and 10,000+ corporate clients across 1,930+ municipalities through 125 owned units and an integrated platform spanning clinical analysis, genomics, imaging, and toxicology.

Ownership category

akta.pro rank

Headquarters

HQ city

Vespasiano

HQ country

Brazil

HQ region

Latin America

Offices15 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Laboratory Diagnostic Services: Clinical analysis, diagnostic imaging, vaccination, cryopreservation, and genetic testing services provided to patients at owned units and through health insurance billing.
2. Laboratory Support Services (Lab-to-Lab): B2B services provided to approximately 6,000 partner laboratories across Brazil, including specialized testing, assessments, and operational support.
3. Health Insurance Operator Services: Services billed through health insurance operators, self-management companies, and health insurance providers.
4. Specialized Testing Services: Toxicology testing, personalized medicine, genetic testing, and other specialized diagnostic services.

Go-to-market motion3 records

Distribution channels6 records

Marketing channels6 records

Core offering

Grupo Pardini is a Brazilian diagnostic medicine group that provides clinical analysis, diagnostic imaging, vaccination, cryopreservation, genetic and genomic testing, toxicology, and personalized medicine services through 125 owned service units and a lab-to-lab B2B support network reaching approximately 6,000 partner laboratories across 1,930 municipalities. The group operates one of the largest automated laboratory production hubs in the world, capable of processing more than 5 million tests per month and up to 160 million tests per year through its Enterprise integrated model.

Product overview

Pardini Group is a Brazilian diagnostic medicine company organized as a multi-brand portfolio spanning clinical analysis, diagnostic imaging, genetics, toxicology, telemedicine, and personalized medicine. The core platform is Hermes Pardini (founded 1959), supported by approximately 6,000 partner laboratories and 125+ owned units. Key acquired brands include Padrão (Goiás), Diagnóstika (pathological anatomy, São Paulo), Progenética (oncology/genomics, Rio de Janeiro), DLE (genetics/rare diseases), BIOCOD (genetic counseling), Centro de Medicina Nuclear da Guanabara (Rio de Janeiro), Ecoar and Humberto Abrão (imaging/clinical analysis, Minas Gerais), Labfar and Toxicologia Pardini (toxicology), and Solução Lab (Southern Brazil). The Enterprise platform (launched 2020) provides the integrated operational backbone, connecting seven production nuclei with capacity for 160 million tests/year and real-time monitoring. The Medicina Personalizada platform aggregates genetics/genomics services across five specialized subsidiaries, offering 8,000+ test types. The group also operates digital platforms My Pardini (customer support) and Telemedicina Pardini.

Differentiator

Problem solved

Functional benefit

Products and services

• Hermes Pardini Clinical Analysis and Imaging Services Flagship brand of the group providing clinical analysis, diagnostic imaging, vaccines, functional tests, cryopreservation, and human/veterinary genetics through owned units in Minas Gerais and São Paulo. Also serves approximately 6,000 partner laboratories across Brazil under the Lab-to-Lab support model.
• Padrão Laboratory (Goiás) Clinical analysis laboratory acquired in July 2013; the largest laboratory in Goiás state, expanding the group's analytical clinical operations and providing an important operational base in Brazil's Center-West region.
• Diagnóstika Anatomical Pathology São Paulo-based anatomical pathology and molecular pathology service with over 30 years of history, specializing in surgical pathology and cytology; positioned as Brazil's largest company in pathological anatomy and molecular pathology services.
• Progenética Oncology Molecular Diagnostics Rio de Janeiro-based molecular oncology reference laboratory specializing in genomics and oncogenetics for cancer diagnostic, prognostic, and therapeutic guidance. One of the first institutions in Brazil to implement high-complexity molecular tests for personalized cancer medicine.
• Centro de Medicina Nuclear da Guanabara (CMNG) Nuclear medicine and clinical analysis provider in Rio de Janeiro state with operations in the capital, Nova Iguaçu, and Campo Grande. Operates for over 40 years with particular expertise in nuclear medicine using radioactive substances for disease diagnosis and treatment.
• Ecoar Diagnostic Imaging Diagnostic imaging center in Belo Horizonte and metropolitan region with nearly 30 years of history, specializing in MRI, CT, echocardiography, vascular duplex scan, ultrasonography, nuclear medicine, and cardiology.
• Laboratório Humberto Abrão Reference laboratory for clinical analysis in Belo Horizonte with 40 years of history, serving the local medical community and premium-segment clients with high-quality services and excellence in customer care.
• Labfar Toxicology Toxicology laboratory specializing in drug abuse detection tests enabling wide detection windows, with INMETRO certification and DENATRAN accreditation for toxicological examinations.
• DLE Human Genetics and Rare Diseases Reference center in human genetics and rare diseases in Brazil, specializing in molecular genetics, biochemical genetics, neonatal screening, and laboratory investigation of inborn errors of metabolism. Pioneer in implementing various genetic techniques and equipment previously unavailable in Brazil.
• BIOCOD Genetic Counseling Genetic counseling and genetic testing services in human genetics and molecular biology following strict quality standards, expanding the group's molecular genetics offering.
• Toxicologia Pardini Wide-detection toxicology services with collection units in nearly 1,000 municipalities and a base of more than 10,000 corporate clients with scientific, market, and social relevance.
• Laboratório Solução Lab-to-Lab support services primarily in Brazil's Southern region, generating operational synergies and improving service quality and delivery times for clients in Santa Catarina and surrounding areas.
• Enterprise Integrated Diagnostic Medicine Platform An Integrated Intelligence Model in Diagnostic Medicine combining state-of-the-art automated equipment, a logistics network reaching 2,000+ municipalities daily, a real-time command center for production monitoring, and digital customer experience tools. Connects a central nucleus near Belo Horizonte International Airport to six advanced nuclei (São Paulo, Rio de Janeiro, Goiânia, Itajaí, and Belo Horizonte). Capacity: up to 160 million tests per year.
• Núcleo Técnico Operacional (NTO) Technical-Operational Center in Vespasiano (MG) featuring a horizontalized production concept with multiple automated and semi-automated lines operating in parallel with dedicated areas for specialized tests. Connected to the Central Sample Distribution (CDA) for expedited processing from receipt to result release. Capable of performing more than 5 million tests per month.
• Guardian Infectious Disease Automation An automated production technology model for molecular biology-based detection of infectious diseases. Operates as Brazil's largest COVID-19 testing center with full traceability and safety, prepared for 20,000 RT-PCR tests per day.
• Medicina Personalizada (Personalized Medicine Platform) A personalized medicine platform leveraging genetics and genomics across oncology, cardiology, neurology, endocrinology, hematology, reproduction, neonatal screening, pharmacogenetics, and medical genetics. Built on five specialized companies (Progenética, Diagnóstika, DLE, BIOCOD, and Hermes Pardini's genetics division). Offers 8,000+ test types.
• Painel de Câncer Hereditário com Análise de CNVs (Hereditary Cancer Panel with CNV Analysis) Hereditary cancer genetic test using NGS with copy number variation (CNV) analysis across multiple cancer predisposition genes in a single technique, enabling faster, more precise diagnosis for patients and families at risk for hereditary cancer syndromes.
• Painel de Câncer de Próstata HRR (CP-HRR) NGS-based prostate cancer HRR panel testing for somatic and potentially germline variants in HRR pathway genes from tumor samples, used to identify metastatic prostate cancer patients eligible for PARP inhibitor targeted therapy via the synthetic lethality mechanism.
• Teste de Deficiência do Reparo por Recombinação Homóloga (HRD) HRD (Homologous Recombination Deficiency) test using the AmoyDx HRD Focus Panel kit to extract tumor DNA, investigate pathogenic variants in BRCA1 and BRCA2, and analyze 24,000 genome-wide SNPs for genomic scar scoring, used to identify ovarian cancer patients eligible for PARP inhibitor therapy.
• Teste de Triagem Neonatal Nova Era (New Era Neonatal Screening) Neonatal screening test combining NGS genetic analysis with LC-MS/MS mass spectrometry and conventional biochemical methods to screen for 300+ potentially treatable diseases. Differentiators include reduced false positives, rapid results within 10 business days when clinically significant biochemical alterations are found, and personalized laudos with scientific advisory support.
• Painel para Câncer de Mama e Ovário Hereditário (Hereditary Breast and Ovarian Cancer Panel) Hereditary breast and ovarian cancer genetic panel analyzing multiple cancer predisposition genes beyond BRCA1/BRCA2 simultaneously via NGS, including CNV analysis. Benefits include patient/family risk identification, genetic counseling, intensive screening for early diagnosis, prophylactic surgery guidance, and targeted therapy eligibility determination.
• Imuno-histoquímica de PD-L1 (PD-L1 Immunohistochemistry) PD-L1 immunohistochemistry assay using anti-PD-L1 clone SP142 on FFPE tumor tissue read under VENTANA BenchMark ULTRA, qualitatively assessing PD-L1 protein expression in tumor-infiltrating immune cells to identify metastatic triple-negative breast cancer patients eligible for anti-PD-1 immunotherapy.
• Telemedicina Pardini Telemedicine service platform enabling remote medical consultations and diagnostic services for patients across Brazil, accessible through a dedicated web platform.
• My Pardini Customer Support Platform Digital support platform providing customer relationship management and administrative services for the group's client support operations, available as both a web platform and mobile application.
• Lab-to-Lab (L2L) B2B Laboratory Support Services B2B laboratory support services serving approximately 6,000 partner laboratories across Brazil with specialized testing, quality assessments, and operational support. Enables smaller laboratories to extend their test menus and access high-complexity diagnostics without capital investment.

Quantifiable outcome

• 160 million tests per year capacity across seven production nuclei
• +5 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature5 records

Scale indicators12 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Grupo Fleury: Fleury is one of Brazil's largest diagnostic medicine groups, with a strong presence in São Paulo and Rio de Janeiro. Competes directly with Pardini in clinical analysis, diagnostic imaging, genetics, and personalized medicine, with a similar multi-channel revenue model.
• Sabin Diagnóstico e Saúde: Sabin is a major Brazilian diagnostic medicine group with national expansion, offering clinical analysis, imaging, and specialized testing. Competes directly with Pardini in mid-tier cities and serves similar insurance and corporate customer segments.
• Dasa (Diagnósticos da América): Dasa is Brazil's largest diagnostic medicine company, offering clinical analysis, imaging, and molecular diagnostics through a national network of owned units and partner labs. It is the closest direct competitor to Pardini in scale, business model (B2B + B2C + insurance billing), and Brazilian footprint.

Broad incumbents

• Sonic Healthcare: Sonic Healthcare is a global medical diagnostics operator with pathology and laboratory services across Australia, Europe, and North America. As a broad incumbent it does not compete in Brazil, but serves as a comparable peer for international roll-up strategies and lab automation at scale.
• Unilabs: Unilabs is a European leader in clinical diagnostics and specialized laboratory testing, operating across multiple geographies with a focus on hub-and-spoke operations. As a broad incumbent it does not directly compete in Brazil, but provides a relevant benchmark for European-style diagnostics consolidation and operational centralization.
• Laboratory Corporation of America (Labcorp): Labcorp is a global leader in clinical laboratory services and diagnostics with a broad portfolio spanning routine, esoteric, and genetic testing. As a broad incumbent it does not directly compete in Brazil, but its centralized lab production and personalized medicine strategy parallels Pardini's Enterprise platform thesis.
• Synlab: Synlab is Europe's largest medical diagnostics services provider, operating centralized laboratory hubs across multiple countries. As a broad incumbent it does not directly compete in Brazil, but its hub-and-spoke centralized production model closely mirrors Pardini's Enterprise platform architecture.
• Quest Diagnostics: Quest Diagnostics is one of the world's largest clinical laboratory services companies, offering routine and advanced diagnostics including genetics. As a broad incumbent it does not directly compete in Brazil, but provides a global benchmark for lab automation, lab-to-lab B2B models, and personalized medicine scale that informs Pardini's strategic trajectory.

Emerging players

• Hilab: Hilab is a Brazilian digital diagnostics startup offering connected point-of-care testing with cloud-based result delivery. Represents an emerging direct competitor in decentralized testing, particularly in occupational health and primary care, where Pardini's Lab-to-Lab model also operates.

Regional players

• BPL Medical (Belo Horizonte Patologia e Laboratórios): BPL Medical is a regional diagnostic laboratory group with strong presence in Minas Gerais and parts of the Southeast, directly overlapping with Pardini's strongest geography. It competes for the same partner labs, hospitals, and patient volumes in BH and surrounding regions.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/hermespardini?lang=pt
• YouTubeyoutube.com/channel/UC4xb0ywnPNE1vOHCJF3aEmg/featured?view_as=subscriber
• Facebookfacebook.com/hermespardini
• LinkedInlinkedin.com/company/grupo-pardini
• Instagraminstagram.com/hermes.pardini/?hl=pt-br

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pardini Group